Latest news
AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof - Dermatology TimesDermatology Times · Tue, 04 Aug 2026 16:08:23 GMTMyelofibrosis: selinexor added to ruxolitinib increases spleen response but not symptom benefit - Vera HealthVera Health · Sat, 01 Aug 2026 04:14:54 GMTKaryopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval - AllSciAllSci · Fri, 31 Jul 2026 12:29:21 GMTKaryopharm to Submit Selinexor-Ruxolitinib sNDA for Myelofibrosis in August 2026 - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 31 Jul 2026 06:32:58 GMTKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway - KaryopharmKaryopharm · Thu, 30 Jul 2026 07:00:00 GMTOpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMT